Affiliation: Wayne State University
- Maximising therapeutic outcomes in patients failing on current therapyChristina Caon
Multiple Sclerosis Center, Department of Neurology, Wayne State University, Detroit, MI, USA
J Neurol Sci 277:S33-6. 2009..Formal switching algorithms need to be developed in order to ensure that all patients who could benefit from such an approach are managed in a timely and optimal manner...
- Injectable disease-modifying therapy for relapsing-remitting multiple sclerosis: a review of adherence dataChristina Caon
Multiple Sclerosis Center at Wayne State University School of Medicine, Detroit, MI, USA
J Neurosci Nurs 42:S5-9. 2010..Nursing interventions that can improve adherence, including telephone counseling and motivational interview techniques, are also addressed...
- Long-term study of brain 1H-MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-Term H-MRS monitoring in multiple sclerosisOmar Khan
Multiple Sclerosis Clinical Research Center, Department of Neurology, The Detroit Medical Center, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
J Neuroimaging 18:314-9. 2008..These data support the long-term effect of GA on maintaining axonal metabolic function and protection from sublethal injury as well as the feasibility of employing brain (1)H-MRS in long-term investigative studies in MS...
- Longitudinal study of the substantia nigra in Parkinson disease: A high-field (1) H-MR spectroscopy imaging studyNavid Seraji-Bozorgzad
The Sastry Foundation Advanced Imaging Laboratory, Department of Neurology, Wayne State University School of Medicine, Detroit, MI, USA
Mov Disord 30:1400-4. 2015..The value of biomarkers in early diagnosis and development of therapeutics in Parkinson's disease (PD) is well established...
- Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI studyOmar Khan
MR Image Analysis Laboratory, Department of Neurology, Wayne State University School of Medicine, Detroit, MI 48201, USA
J Neurol Sci 312:7-12. 2012..To compare the long-term effect of disease-modifying therapies (DMT) on brain volume loss in relapsing-remitting MS (RRMS) patients...
- Acute transverse myelitis with normal brain MRI : long-term risk of MSJui Perumal
Multiple Sclerosis Center, Dept of Neurology, Wayne State University School of Medicine, Detroit, MI, USA
J Neurol 255:89-93. 2008..To investigate the long-term risk of developing MS in patients presenting with acute transverse myelitis (ATM) and normal brain MRI scans at onset...
- Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative studyAaron Boster
Department of Neurology, Wayne State University School of Medicine, Detroit, MI 48201, USA
Arch Neurol 66:593-9. 2009..To identify clinical and magnetic resonance imaging (MRI) features that distinguish progressive multifocal leukoencephalopathy (PML) from relapsing-remitting multiple sclerosis (RRMS)...
- Spinal cord atrophy in multiple sclerosis and relationship with disability across clinical phenotypesEvanthia Bernitsas
Multiple Sclerosis Center, Wayne State University School of Medicine, Detroit, USA
Mult Scler Relat Disord 4:47-51. 2015..Several studies have shown a relationship between spinal cord atrophy and clinical disability in patients with multiple sclerosis (MS)...
- Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosisOmar Khan
Department of Neurology, Multiple Sclerosis Center, Wayne State University School of Medicine, Detroit, MI 48201, USA
Mult Scler 11:646-51. 2005..These results support an in situ effect of GA therapy inside the CNS and suggest potential neuroprotective effects of GA...
- Pediatric-onset multiple sclerosis in African-American black and European-origin white patientsAaron L Boster
Department of Neurology, The Ohio State University, Columbus, Ohio, USA
Pediatr Neurol 40:31-3. 2009..50; P < 0.001). These findings are consistent with data suggesting a more aggressive disease phenotype among African-American blacks with adult-onset multiple sclerosis. Larger multicenter studies are warranted to confirm the findings...
- Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosisOmar Khan
Department of Neurology, Multiple Sclerosis Center, Wayne State University School of Medicine, D University Health Center, 4201 St Antoine, Detroit, MI 48201, USA
CNS Drugs 16:563-78. 2002..In a pharmaceutical environment with an estimated worldwide market of $US2.5 billion annually for RRMS, comparative studies are understandably provocative, but at the same time provide meaningful information to clinicians and patients...